Eisai ‘Very Confident’ of Full US Nod for Alzheimer’s Drug (1)

Eisai Co. is “very confident” of winning full approval from US regulators for its Alzheimer’s drug Leqembi, said Ivan Cheung, Eisai’s global Alzheimer’s disease officer.

Clearing that hurdle will expand access of the medicine to about 10,000 patients in the US by the end of the fiscal year to March 2024, according to Cheung.

Leqembi has an advantage over its competitor Donanemab developed by Eli Lilly & Co. because Eisai’s drug can treat broader patient populations and be used in earlier stages of Alzheimer’s disease, Cheung said in a post-earnings briefing held Monday. It’s “critically important” to use it ...